Back to top
more

QIAGEN (QGEN)

(Delayed Data from NYSE)

$46.36 USD

46.36
946,981

+0.79 (1.73%)

Updated Sep 13, 2024 04:00 PM ET

After-Market: $46.38 +0.02 (0.04%) 7:58 PM ET

Zacks Rank:

This is our short term rating system that serves as a timeliness indicator for stocks over the next 1 to 3 months. How good is it? See rankings and related performance below.

Zacks Rank Definition Annualized Return
1Strong Buy23.68%
2Buy17.55%
3Hold9.21%
4Sell4.93%
5Strong Sell2.36%
S&P50010.96%

Zacks Rank Education - Learn about the Zacks Rank

Zacks Rank Home - Zacks Rank resources in one place

Zacks Premium - The only way to fully access the Zacks Rank

3-Hold of 5     3    

Style Scores:

The Style Scores are a complementary set of indicators to use alongside the Zacks Rank. It allows the user to better focus on the stocks that are the best fit for his or her personal trading style.

The scores are based on the trading styles of Value, Growth, and Momentum. There's also a VGM Score ('V' for Value, 'G' for Growth and 'M' for Momentum), which combines the weighted average of the individual style scores into one score.

Value Score A
Growth Score A
Momentum Score A
VGM Score A

Within each Score, stocks are graded into five groups: A, B, C, D and F. As you might remember from your school days, an A, is better than a B; a B is better than a C; a C is better than a D; and a D is better than an F.

As an investor, you want to buy stocks with the highest probability of success. That means you want to buy stocks with a Zacks Rank #1 or #2, Strong Buy or Buy, which also has a Score of an A or a B in your personal trading style.

Zacks Style Scores Education - Learn more about the Zacks Style Scores

C Value C Growth C Momentum C VGM

Industry Rank:

The Zacks Industry Rank assigns a rating to each of the 265 X (Expanded) Industries based on their average Zacks Rank.

An industry with a larger percentage of Zacks Rank #1's and #2's will have a better average Zacks Rank than one with a larger percentage of Zacks Rank #4's and #5's.

The industry with the best average Zacks Rank would be considered the top industry (1 out of 265), which would place it in the top 1% of Zacks Ranked Industries. The industry with the worst average Zacks Rank (265 out of 265) would place in the bottom 1%.

Zacks Rank Education -- Learn more about the Zacks Rank
Zacks Industry Rank Education -- Learn more about the Zacks Industry Rank

Top 33% (83 out of 251)

Industry: Medical - Biomedical and Genetics

Better trading starts here.

Zacks News

QIAGEN (QGEN) Q2 Earnings Top Estimates, Margins Decline

QIAGEN (QGEN) posts better-than-expected results for the second quarter and raises its sales and earnings outlook for 2022 amid the uncertain macroeconomic environment.

Qiagen (QGEN) Beats Q2 Earnings and Revenue Estimates

Qiagen (QGEN) delivered earnings and revenue surprises of 13.33% and 3.50%, respectively, for the quarter ended June 2022. Do the numbers hold clues to what lies ahead for the stock?

QIAGEN (QGEN) QCI's Robust Adoption to Enhance Patient Outcome

QIAGEN's (QGEN) QCI platform is expected to significantly streamline NGS data analysis and variant interpretation, and enable swift and confident shift by users from raw NGS data to clinical report.

Biohaven Pharmaceutical Holding Company Ltd. (BHVN) Up 2.8% Since Last Earnings Report: Can It Continue?

Biohaven Pharmaceutical Holding Company Ltd. (BHVN) reported earnings 30 days ago. What's next for the stock? We take a look at earnings estimates for some clues.

Why Is Novavax (NVAX) Down 11.7% Since Last Earnings Report?

Novavax (NVAX) reported earnings 30 days ago. What's next for the stock? We take a look at earnings estimates for some clues.

Why Is Fate Therapeutics (FATE) Down 14.1% Since Last Earnings Report?

Fate Therapeutics (FATE) reported earnings 30 days ago. What's next for the stock? We take a look at earnings estimates for some clues.

Why Is Qiagen (QGEN) Up 0.1% Since Last Earnings Report?

Qiagen (QGEN) reported earnings 30 days ago. What's next for the stock? We take a look at earnings estimates for some clues.

Here's Why You Should Retain QIAGEN (QGEN) Stock for Now

Investors are optimistic about QIAGEN (QGEN), owing to strong international growth and bullish guidance.

QIAGEN (QGEN) Unveils New Enhancements to QIAstat-Dx Portfolio

The launch of QIAstat-Dx Rise and other advancements to the QIAstat-Dx portfolio are expected to strengthen QIAGEN's (QGEN) syndromic testing solutions.

QIAGEN (QGEN) to Acquire Poland-Based Enzymes Manufacturer

The latest acquisition of BLIRT will allow QIAGEN (QGEN) to tap into the high opportunities within the life science industry.

Syneos Health (SYNH) Q1 Earnings Top Estimates, Margins Up

Syneos Health's (SYNH) revenues increased year over year in the first quarter, led by strong performances by the Clinical Solutions and Commercial Solutions arms.

Surmodics (SRDX) Beats on Q2 Earnings, Revises FY22 View

Despite solid IVD revenues, Surmodics (SRDX) reports a soft Q2 overall top line.

Teleflex's (TFX) Q1 Earnings Top Estimates, Margins Down

Teleflex (TFX) exhibits year-over-year growth across the Americas, EMEA and Asia regions at CER in the first quarter.

Accuray (ARAY) Q3 Earnings Beat Estimates, Revenues Lag

Despite strong product demand, Accuray (ARAY) reports an overall soft Q3 performance.

Bio-Rad (BIO) Q1 Earnings Surpass Estimates, Margins Up

Bio-Rad's (BIO) first-quarter 2022 revenues decline year over year due to lower COVID-related demand.

QIAGEN (QGEN) Q1 Earnings Surpass Estimates, 2022 View Up

QIAGEN (QGEN) exited first-quarter 2022 with better-than-expected results on strength in the non-COVID product portfolio driving the top line.

Stryker (SYK) Q1 Earnings and Revenues Surpass Estimates

Stryker's (SYK) first-quarter earnings reflect strong performance across its segments.

DexCom (DXCM) Q1 Earnings Miss, Revenues Beat Estimates

Despite a decline in bottom line, DexCom's (DXCM) first-quarter results benefit from domestic and international revenue growth and solid new customer additions.

Merit Medical (MMSI) Q1 Earnings Beat, FY22 View Unchanged

Merit Medical (MMSI), in the first quarter, benefits from revenue growth in both its segments and from all of the product categories within its Cardiovascular unit.

Hologic (HOLX) Q2 Earnings Surpass Estimates, 2022 View Up

Hologic's (HOLX) second-quarter 2022 revenues decline year over year primarily due to lower COVID-19 assay sales compared to the prior year.

LabCorp (LH) Q1 Earnings Surpass Estimates, Revenues Miss

LabCorp (LH) reports better-than-expected earnings for the first quarter, with robust sales within the Drug Development arm driving the top line.

Thermo Fisher (TMO) Q1 Earnings Beat Estimates, Margins Down

The robust year-over-year revenue growth across Thermo Fisher's (TMO) Analytical Instruments and the Laboratory Products and Biopharma Services segments appears promising.

Baxter (BAX) Q1 Earnings and Revenues Surpass Estimates

Baxter's (BAX) first-quarter results reflect robust performance across four of its business units.

West Pharmaceutical (WST) Q1 Earnings Top Estimates, Revenues Lag

West Pharmaceutical's (WST) first-quarter earnings reflect strength in the Proprietary Products segment and operating margin expansion.

Align Technology (ALGN) Q1 Earnings Lag Estimates, Margins Fall

Robust Clear Aligner case volume growth and increased uptake of the iTero Element 5D Plus are driving Align Technology's (ALGN) first-quarter top line.